CM
KITE

Castleark Management’s Kite Pharma, Inc. KITE Stock Holding History

Castleark Management’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-43,110
Closed -$3.38M – 448
2017
Q1 		$3.38M Buy
+43,110
New +$2.67M 0.11% 227

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Castleark Management's KITE Position: Q2 2017 in Review

Castleark Management sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 43,110 shares — an estimated $3.38M sold.

Castleark Management first reported a position in KITE in Q1 2017 and held it in 1 quarter. The position peaked at $3.38M in Q1 2017. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

  • Castleark Management reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
  • Castleark Management sold 43,110 Kite Pharma, Inc. shares in Q2 2017, an estimated $3.38M.
  • Castleark Management first reported a position in Kite Pharma, Inc. in Q1 2017 and held it in 1 quarter.
  • Castleark Management's Kite Pharma, Inc. position peaked at $3.38M in Q1 2017.
  • 220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on Castleark Management's 13F filing for Q2 2017, filed 15 Aug 2017.